M281 is a fully human, anti‐neonatal Fc receptor (FcRn) antibody that inhibits FcRn‐
mediated immunoglobulin G (IgG) recycling to decrease pathogenic IgG while preserving …

IgGs are essential soluble components of the adaptive immune response that evolved to
protect the body from infection. Compared with other immunoglobulins, the role of IgGs is …

The therapeutic management of antibody-mediated autoimmune disease typically involves
immunosuppressant and immunomodulatory strategies. However, perturbing the …

The neonatal fragment crystallizable (Fc) receptor (FcRn) functions as a recycling
mechanism to prevent degradation and extend the half-life of IgG and albumin in the …

The neonatal Fc receptor (FcRn) is a key determinant of IgG homeostasis. It binds to the Fc
domain of IgG in a strictly pH-dependent manner and protects IgG from lysosomal …

The pH-dependent binding of IgGs to the neonatal Fc receptor (FcRn) plays a critical role in
regulating IgG homeostasis in vivo. Enhancing interactions between Fc and FcRn via protein …

The neonatal Fc receptor (FcRn) is important for the metabolic fate of IgG antibodies in vivo.
Analysis of the interaction between FcRn and IgG in vitro might provide insight into the …

The neonatal Fc receptor (FcRn) plays a critical role in regulating IgG homeostasis in vivo.
There are mixed reports on whether modification of the interaction with FcRn can be used as …

The majority of potent new biologics today are IgG-based molecules that have demonstrated
tissue-targeting specificity with favorable clinical response. Several factors determine the …

ABSTRACT Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal
Fc receptor (FcRn) monoclonal antibody (IgG4P), has been developed to reduce pathogenic …